Novavax transfers U.S. marketing authorization for Nuvaxovid to Sanofi

Novavax (NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid to Sanofi (SNY), enabling Sanofi to take full responsibility for commercial and regulatory activities in the U.S. and fulfilling part of its collaboration and license agreement. The transfer triggered the second of two $25M marketing authorization transfer milestone payments to Novavax, following the European Union transfer completed in October 2025. “With the successful achievement of our BLA approval and completion of both U.S. and EU marketing authorization transfers for Nuvaxovid(TM) to Sanofi, we have delivered on our partnership agreement and secured $225 million in additional milestone revenue to date,” said John Jacobs, President and Chief Executive Officer, Novavax. “We look forward to Sanofi’s success in globally marketing our protein-based, non-mRNA COVID-19 vaccine in the years to come.” Novavax is eligible to receive additional future milestones and royalties under the CLA related to Nuvaxovid, combination products developed by Sanofi using Nuvaxovid and new vaccines created by Sanofi utilizing Novavax’s Matrix-M adjuvant.